Streetbeat News

Earnings

MBRX

Moleculin Biotech, Inc. presented data for its anthracycline product, indicating progress in its development. This could impact investor sentiment and the company's stock price.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:34 pm

AXIL

AXIL Brands, Inc. (NYSE:AXIL) reported a Q3 EPS of $0.04, up from $0.01 YoY, with revenue increasing 14.4% to approximately $6.47M. Gross profit margin decreased to 71.5% from 74.6%, and operating expenses rose to 73.1% of net revenue. The company also reported a net income of $781,091. Key updates include a rebranding to AXIL Brands, Inc., uplisting to the NYSE American Stock Exchange, and a significant repurchase of Series A preferred shares, reducing outstanding shares by approximately 55% on a fully diluted basis.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:34 pm

AIM

AIM ImmunoTech announced interim report data from a study of Ampligen combined with Pembrolizumab for recurrent ovarian cancer. The study's results could influence the company's stock performance in the short term.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:22 pm

MAIN

NYCB

STWD

Wall Street's most accurate analysts have provided updates on three financial stocks with over 6% dividend yields: Main Street Capital Corporation (MAIN), New York Community Bancorp, Inc. (NYCB), and Starwood Property Trust, Inc. (STWD). MAIN received a price target increase from both Truist Securities and RBC Capital following upbeat quarterly earnings. NYCB was downgraded by Raymond James and had its price target cut by Keefe, Bruyette & Woods after announcing a significant equity investment. STWD maintained positive ratings from Wells Fargo and JP Morgan, with both analysts raising their price targets ahead of its Q1 2024 financial results release.

Portfolio Pulse from Avi Kapoor

April 10, 2024 | 12:13 pm

ASTI

MRIN

PSMT

PriceSmart, Inc. (NASDAQ:PSMT) shares rose by approximately 5% in pre-market trading after reporting Q2 earnings of $1.31 per share, surpassing estimates of $1.25 per share, with sales of $1.29 billion against expected $1.28 billion. Other stocks also showed significant movement in pre-market trading, with notable gainers including Marin Software, iCoreConnect, and Nano Labs, and losers such as FutureFuel Corp, Destiny Tech100, and PainReform Ltd.

Portfolio Pulse from Avi Kapoor

April 10, 2024 | 12:12 pm

NDLS

PLCE

UAA

The article highlights the top 3 oversold stocks in the consumer staples sector, identified by their low RSI values, indicating potential undervaluation. Noodles & Company (NDLS), The Children's Place, Inc. (PLCE), and Under Armour, Inc. (UAA) are mentioned as having RSI values near or below 30, suggesting they may be poised for a rebound. NDLS faced a 30% stock decline after weak Q4 results, PLCE received a significant financing tranche but saw a 48% stock decline, and UAA was downgraded by Evercore ISI Group, leading to an 18% stock decline.

Portfolio Pulse from Avi Kapoor

April 10, 2024 | 12:12 pm

HXL

KITT

SNTG

UAL

VLD

In Wednesday's pre-market session, there were notable movements in the industrials stocks sector. Sentage Holdings, Nauticus Robotics, Desktop Metal, Gaucho Group Holdings, United Airlines Holdings, and SKYX Platforms saw gains, with increases ranging from 4.54% to 8.6%. On the downside, Velo3D, Palladyne AI, Vast Renewables, Hexcel, Laser Photonics, and Azul experienced declines between 7.64% and 16.0%. Nauticus Robotics' rise was attributed to its Q4 earnings report released the previous day.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 12:09 pm

CYTO

Altamira Therapeutics reported a significant improvement in its fiscal year GAAP EPS, moving from CHF(409.60) to CHF(14.80) year-over-year. Additionally, the company's other operating income increased from CHF9.33K to CHF255.59K over the same period.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:06 pm

GREE

Greenidge Generation Holdings (NASDAQ:GREE) reported Q4 earnings of $0.36 per share, surpassing the $0.28 estimate, marking a 105.9% increase from last year. However, their Q4 sales of $19.60M fell short of the $26.70M estimate, despite being a 22.41% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:04 pm

ATRC

AtriCure (NASDAQ:ATRC) has received updated analyst ratings, with a consensus indicating a bullish outlook. Over the past three months, four analysts have rated ATRC as bullish, with recent adjustments in price targets reflecting a slight decrease in the average target to $48.00 from $50.33. AtriCure's financial performance shows strong revenue growth and profitability, with a notable net margin and ROE. The company specializes in surgical treatments for atrial fibrillation and other related conditions, primarily serving the U.S. market.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 12:01 pm